Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gout | 23 | 2024 | 573 | 5.570 |
Why?
|
| Hyperuricemia | 7 | 2022 | 211 | 2.120 |
Why?
|
| Uric Acid | 11 | 2024 | 766 | 2.080 |
Why?
|
| Gout Suppressants | 6 | 2022 | 166 | 1.140 |
Why?
|
| Allopurinol | 4 | 2022 | 191 | 1.060 |
Why?
|
| Efficiency | 2 | 2019 | 462 | 1.010 |
Why?
|
| Clinical Coding | 3 | 2015 | 171 | 1.000 |
Why?
|
| Lupus Erythematosus, Systemic | 5 | 2023 | 2104 | 0.990 |
Why?
|
| Antirheumatic Agents | 4 | 2023 | 1339 | 0.930 |
Why?
|
| Rheumatic Diseases | 3 | 2021 | 592 | 0.880 |
Why?
|
| Biological Products | 2 | 2020 | 860 | 0.750 |
Why?
|
| Colchicine | 2 | 2021 | 243 | 0.740 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2024 | 2208 | 0.710 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2023 | 293 | 0.680 |
Why?
|
| Health Occupations | 1 | 2020 | 224 | 0.670 |
Why?
|
| British Columbia | 7 | 2021 | 244 | 0.630 |
Why?
|
| Sjogren's Syndrome | 1 | 2019 | 233 | 0.580 |
Why?
|
| Databases, Factual | 7 | 2024 | 7729 | 0.550 |
Why?
|
| Absenteeism | 1 | 2017 | 250 | 0.540 |
Why?
|
| Hospitalization | 9 | 2024 | 10262 | 0.540 |
Why?
|
| Autoimmune Diseases | 2 | 2017 | 2133 | 0.520 |
Why?
|
| Myocardial Infarction | 3 | 2023 | 11727 | 0.510 |
Why?
|
| Scleroderma, Systemic | 1 | 2019 | 323 | 0.510 |
Why?
|
| Commerce | 1 | 2020 | 592 | 0.490 |
Why?
|
| Cardiovascular Agents | 1 | 2021 | 850 | 0.480 |
Why?
|
| Primary Prevention | 1 | 2020 | 1167 | 0.440 |
Why?
|
| International Classification of Diseases | 2 | 2015 | 867 | 0.410 |
Why?
|
| Medicaid | 2 | 2021 | 2736 | 0.350 |
Why?
|
| Insulin Resistance | 2 | 2021 | 3864 | 0.320 |
Why?
|
| Population Surveillance | 1 | 2019 | 2616 | 0.310 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 7785 | 0.300 |
Why?
|
| Stroke | 2 | 2023 | 9981 | 0.300 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 1257 | 0.290 |
Why?
|
| Diuretics | 2 | 2020 | 592 | 0.290 |
Why?
|
| Health Surveys | 1 | 2017 | 4037 | 0.290 |
Why?
|
| Health Expenditures | 1 | 2020 | 2348 | 0.290 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2019 | 3712 | 0.290 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 5391 | 0.270 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 3336 | 0.270 |
Why?
|
| Health Care Costs | 1 | 2019 | 3209 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2021 | 15519 | 0.260 |
Why?
|
| Medicare | 2 | 2021 | 6566 | 0.260 |
Why?
|
| Diet, Mediterranean | 2 | 2022 | 700 | 0.240 |
Why?
|
| Death Certificates | 2 | 2015 | 169 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2023 | 17446 | 0.230 |
Why?
|
| Nutrition Surveys | 4 | 2023 | 1660 | 0.220 |
Why?
|
| Humans | 43 | 2024 | 744343 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 11725 | 0.210 |
Why?
|
| Middle Aged | 22 | 2024 | 213383 | 0.200 |
Why?
|
| Obesity | 6 | 2021 | 12745 | 0.200 |
Why?
|
| Hydroxychloroquine | 2 | 2023 | 412 | 0.190 |
Why?
|
| Incidence | 6 | 2022 | 20947 | 0.190 |
Why?
|
| Prevalence | 6 | 2023 | 15226 | 0.180 |
Why?
|
| Cohort Studies | 7 | 2023 | 40561 | 0.180 |
Why?
|
| Risk Factors | 12 | 2023 | 72290 | 0.170 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2023 | 967 | 0.170 |
Why?
|
| Health Status Disparities | 2 | 2023 | 1797 | 0.170 |
Why?
|
| Male | 24 | 2024 | 350118 | 0.170 |
Why?
|
| Adult | 17 | 2023 | 214055 | 0.170 |
Why?
|
| Female | 26 | 2024 | 380194 | 0.170 |
Why?
|
| Aged | 17 | 2023 | 163280 | 0.160 |
Why?
|
| Arthralgia | 1 | 2022 | 456 | 0.160 |
Why?
|
| Depression | 1 | 2017 | 7766 | 0.160 |
Why?
|
| Diet, Fat-Restricted | 1 | 2020 | 320 | 0.150 |
Why?
|
| Sodium | 1 | 2023 | 1623 | 0.150 |
Why?
|
| San Francisco | 1 | 2017 | 159 | 0.150 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2020 | 262 | 0.150 |
Why?
|
| Alcohol Drinking | 2 | 2020 | 3966 | 0.150 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 39050 | 0.150 |
Why?
|
| Dietary Fiber | 1 | 2021 | 760 | 0.150 |
Why?
|
| Prescriptions | 1 | 2019 | 387 | 0.150 |
Why?
|
| Retinal Diseases | 1 | 2023 | 683 | 0.140 |
Why?
|
| Drug Eruptions | 1 | 2019 | 297 | 0.140 |
Why?
|
| Drugs, Generic | 1 | 2021 | 421 | 0.140 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 25043 | 0.130 |
Why?
|
| Body Mass Index | 3 | 2021 | 12720 | 0.130 |
Why?
|
| Heart Failure | 2 | 2019 | 10900 | 0.120 |
Why?
|
| Drug Approval | 1 | 2021 | 742 | 0.120 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 1584 | 0.110 |
Why?
|
| Prospective Studies | 6 | 2023 | 53288 | 0.110 |
Why?
|
| Life Style | 2 | 2021 | 3835 | 0.100 |
Why?
|
| Hypertension | 3 | 2021 | 8480 | 0.100 |
Why?
|
| Recurrence | 1 | 2024 | 8340 | 0.100 |
Why?
|
| Genetic Loci | 1 | 2021 | 2575 | 0.100 |
Why?
|
| Adiposity | 1 | 2021 | 1807 | 0.100 |
Why?
|
| Workplace | 1 | 2017 | 836 | 0.100 |
Why?
|
| Glucose | 1 | 2023 | 4397 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2023 | 2872 | 0.100 |
Why?
|
| Venous Thromboembolism | 2 | 2021 | 1671 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 1239 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2017 | 985 | 0.090 |
Why?
|
| Vaccines | 1 | 2019 | 822 | 0.090 |
Why?
|
| Risk Assessment | 5 | 2024 | 23338 | 0.090 |
Why?
|
| Glucocorticoids | 2 | 2016 | 2107 | 0.090 |
Why?
|
| Social Class | 1 | 2019 | 1999 | 0.090 |
Why?
|
| Immunologic Factors | 1 | 2019 | 1580 | 0.090 |
Why?
|
| United States | 7 | 2023 | 69872 | 0.090 |
Why?
|
| Educational Status | 1 | 2017 | 2540 | 0.090 |
Why?
|
| Ischemic Attack, Transient | 1 | 2015 | 935 | 0.090 |
Why?
|
| Self Report | 1 | 2020 | 3558 | 0.090 |
Why?
|
| Myocardial Ischemia | 1 | 2019 | 2148 | 0.080 |
Why?
|
| Income | 1 | 2017 | 1913 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2015 | 1504 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 3158 | 0.080 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2015 | 1018 | 0.080 |
Why?
|
| Pain | 1 | 2022 | 4986 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 3022 | 0.070 |
Why?
|
| Cost of Illness | 1 | 2017 | 1859 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 2376 | 0.070 |
Why?
|
| Vaccination | 1 | 2019 | 3278 | 0.070 |
Why?
|
| Insulin | 1 | 2021 | 6580 | 0.070 |
Why?
|
| Diet | 5 | 2023 | 7939 | 0.070 |
Why?
|
| Poverty | 1 | 2017 | 2660 | 0.070 |
Why?
|
| Diabetes Mellitus | 2 | 2021 | 5751 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2024 | 77449 | 0.060 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2024 | 85 | 0.060 |
Why?
|
| Cerebral Hemorrhage | 1 | 2015 | 2647 | 0.060 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 7659 | 0.060 |
Why?
|
| Mental Health | 1 | 2017 | 3019 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2021 | 21746 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 13989 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2017 | 4245 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 3047 | 0.050 |
Why?
|
| Cardiovascular Diseases | 3 | 2024 | 15165 | 0.050 |
Why?
|
| Research Design | 1 | 2017 | 5987 | 0.050 |
Why?
|
| Myocardium | 1 | 2014 | 4776 | 0.050 |
Why?
|
| Comorbidity | 3 | 2021 | 10388 | 0.050 |
Why?
|
| Smoking | 1 | 2017 | 8987 | 0.050 |
Why?
|
| Renal Replacement Therapy | 1 | 2021 | 257 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 14722 | 0.040 |
Why?
|
| Israel | 1 | 2020 | 796 | 0.040 |
Why?
|
| Nutrition Policy | 1 | 2022 | 488 | 0.040 |
Why?
|
| Sulfinpyrazone | 1 | 2016 | 14 | 0.040 |
Why?
|
| Diet, Reducing | 1 | 2020 | 462 | 0.040 |
Why?
|
| Uricosuric Agents | 1 | 2016 | 28 | 0.040 |
Why?
|
| Probenecid | 1 | 2016 | 76 | 0.040 |
Why?
|
| Population Growth | 1 | 2016 | 52 | 0.040 |
Why?
|
| Sex Factors | 2 | 2021 | 10397 | 0.040 |
Why?
|
| Young Adult | 3 | 2021 | 56430 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2017 | 513 | 0.030 |
Why?
|
| Fruit | 1 | 2021 | 1142 | 0.030 |
Why?
|
| Vegetables | 1 | 2021 | 1182 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2023 | 2263 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2020 | 2297 | 0.030 |
Why?
|
| Canada | 1 | 2020 | 2065 | 0.030 |
Why?
|
| Age Distribution | 1 | 2020 | 2902 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 2029 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2016 | 1105 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 1125 | 0.030 |
Why?
|
| Reference Values | 1 | 2020 | 4982 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 13102 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 15540 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 789 | 0.020 |
Why?
|
| Cause of Death | 1 | 2021 | 3584 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2022 | 63114 | 0.020 |
Why?
|
| Prognosis | 2 | 2021 | 29063 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 2569 | 0.020 |
Why?
|
| Time Factors | 2 | 2021 | 40075 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 57776 | 0.020 |
Why?
|
| Weight Loss | 1 | 2020 | 2622 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2021 | 9849 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 1972 | 0.020 |
Why?
|
| Overweight | 1 | 2019 | 2371 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3679 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 10943 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2020 | 10252 | 0.020 |
Why?
|
| Linear Models | 1 | 2017 | 5952 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2282 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 12245 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 12354 | 0.020 |
Why?
|
| Logistic Models | 1 | 2019 | 13408 | 0.020 |
Why?
|
| Age Factors | 1 | 2019 | 18370 | 0.010 |
Why?
|
| Adolescent | 1 | 2021 | 85781 | 0.010 |
Why?
|
Concepts
(173)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(25)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_